APA (7th ed.) Citation

BO, T., Y, Z., K, R., L, B., JD, R., KK, S., . . . P, T. (2026). Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 82(1), 100. https://doi.org/10.1093/cid/ciaf375

Chicago Style (17th ed.) Citation

BO, Taiwo, et al. "Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 82, no. 1 (2026): 100. https://doi.org/10.1093/cid/ciaf375.

MLA (9th ed.) Citation

BO, Taiwo, et al. "Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 82, no. 1, 2026, p. 100, https://doi.org/10.1093/cid/ciaf375.